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Background. Bezlotoxumab is a human monoclonal antibody against Clostridium difficile toxin B indicated to prevent C. diffi-
cile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI. This post hoc analysis of pooled monocolonal antibodies for 
C. difficile therapy (MODIFY) I/II data assessed bezlotoxumab efficacy in participants with characteristics associated with increased 
risk for rCDI.
Methods. The analysis population was the modified intent-to-treat population who received bezlotoxumab or placebo (n = 1554) 
by risk factors for rCDI that were prespecified in the statistical analysis plan: age ≥65 years, history of CDI, compromised immunity, 
severe CDI, and ribotype 027/078/244. The proportion of participants with rCDI in 12 weeks, fecal microbiota transplant procedures, 
30-day all cause and CDI-associated hospital readmissions, and mortality at 30 and 90 days after randomization were presented.
Results. The majority of enrolled participants (75.6%) had ≥1 risk factor; these participants were older and a higher proportion 
had comorbidities compared with participants with no risk factors. The proportion of placebo participants who experienced rCDI 
exceeded 30% for each risk factor compared with 20.9% among those without a risk factor, and the rCDI rate increased with the 
number of risk factors (1 risk factor: 31.3%; ≥3 risk factors: 46.1%). Bezlotoxumab reduced rCDI, fecal microbiota transplants, and 
CDI-associated 30-day readmissions in participants with risk factors for rCDI.
Conclusions. The risk factors prespecified in the MODIFY statistical analysis plan are appropriate to identify patients at high 
risk for rCDI. While participants with ≥3 risk factors had the greatest reduction of rCDI with bezlotoxumab, those with 1 or 2 risk 
factors may also benefit.
Clinical Trials Registration. NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).
Keywords. C. difficile infection; CDI; recurrence; bezlotoxumab.
Clostridium difficile is a gram-positive, anaerobic, spore- forming 
bacillus, ubiquitous in nature and able to survive long periods in the 
environment. Clostridium difficile infection (CDI) occurs in the gas-
trointestinal tract of individuals whose normal gut microbiota has 
been disrupted, usually by prior antimicrobial use, leading to loss 
of colonization resistance and opportunistic infection with C. diffi-
cile [1]. Treatment requires specific antibiotic therapy to eliminate 
C. difficile from the colon; however, after completing initial antibiotic 
therapy with metronidazole or vancomycin, approximately 25% of 
patients have recurrent CDI (rCDI) [2, 3], and approximately 40% 
with a first recurrence experience a second recurrence [4]. Certain 
host or pathogen factors have been associated with an increased 
risk of rCDI or CDI-related adverse outcomes: age ≥65 years [5, 6], 
compromised immunity [7], severe CDI [8, 9], prior CDI epi-
sode(s) [4], and infection with the BI/NAP1/027 strain [5, 10–12]. 
As the incidence of rCDI is rising, there is an unmet need for ther-
apies to prevent rCDI [13].
In 2 global, phase 3 trials (monocolonal antibodies for C. dif-
ficile  therapy  [MODIFY] I  and MODIFY II), bezlotoxumab, 
a human monoclonal antibody against C.  difficile toxin B, 
demonstrated significant reductions in CDI recurrence com-
pared with placesbo (17% vs 28% in MODIFY I  and 16% vs 
26% in MODIFY II; P  <  .001) in adults receiving antibiotic 
treatment for primary CDI or rCDI [14]. To identify the pop-
ulation that may benefit most from bezlotoxumab treatment, 
the current analysis pooled data from the MODIFY studies 
to assess the efficacy of bezlotoxumab in participants with the 
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characteristics listed above that are associated with increased 
risk for rCDI.
METHODS
MODIFY I (NCT01241552) and II (NCT01513239) were inde-
pendent, randomized, double-blind, placebo-controlled, mul-
ticenter phase 3 trials with nearly identical design, conducted 
from November 2011 through May 2015 at 322 sites in 30 coun-
tries. The protocols and all amendments were approved by the 
institutional review board or independent ethics committee 
at each study center. Each study was conducted in accordance 
with Good Clinical Practice Guidelines and the Declaration of 
Helsinki. Written informed consent was obtained before study 
procedures were performed.
Adults with primary or rCDI receiving antibacterial treat-
ment (determined by the treating physician) for CDI were 
enrolled. Eligibility criteria were previously described [14]. 
CDI was defined as diarrhea (≥3 unformed bowel movements 
in 24 hours) associated with a positive stool test for toxigenic 
C. difficile or its toxin(s). Participants included in this subgroup 
analysis received either 1 dose of bezlotoxumab 10  mg/kg or 
placebo (0.9% saline) during antibacterial drug treatment for 
CDI. Randomization was stratified by oral antibacterial treat-
ment (metronidazole, vancomycin, or fidaxomicin) and hos-
pitalization status (inpatient or outpatient). The number of 
unformed bowel movements was recorded by participants daily 
through 12 weeks and new episodes of diarrhea were monitored 
via scheduled phone contacts between visits.
Population, Endpoints, and Statistical Methods
The analysis population was the modified intent-to-treat (mITT) 
population (defined as all randomly assigned participants who 
received study infusion, had a positive toxigenic C.  difficile–
positive stool test, and received standard-of-care [SOC] therapy 
within 1 day of receiving treatment) in the pooled dataset from 
MODIFY I and MODIFY II, who received bezlotoxumab or pla-
cebo, and was further categorized based on known risk factors for 
rCDI or CDI-related adverse outcomes that had been prespeci-
fied at the time of protocol development in the statistical analysis 
plan: age ≥65  years, history of CDI in the previous 6  months, 
compromised immunity, severe CDI (Zar score ≥2 points) at time 
of randomization, and isolation of a strain associated with poor 
outcomes (ribotypes 027, 078, or 244). Use of concomitant sys-
temic antibiotics, although a known risk factor for rCDI [15], was 
not prespecified as a risk factor for subgroup analysis because only 
risk factors present at the time of randomization were included.
Endpoints included proportion of participants who achieved 
initial clinical cure, where initial clinical cure is defined as no 
diarrhea for 2 consecutive days after completion of antibiotic 
therapy administered for ≤16 calendar days; proportion of par-
ticipants with rCDI, where rCDI is defined as the development 
of a new episode of diarrhea associated with a positive stool test 
for toxigenic C. difficile within 12 weeks following study med-
ication infusion assessed in mITT participants who achieved 
initial clinical cure (clinical cure population); proportion of 
participants who received a fecal microbiota transplant (FMT), 
proportion of participants who experienced 30-day all cause 
and CDI-associated hospital readmissions as defined previously 
[16] in mITT participants who were in a healthcare facility at 
the time of randomization; and proportion of participants who 
had died at 30 and 60 days after randomization.
Observed rates for rCDI along with differences between the 
bezlotoxumab and placebo groups and their 95% confidence 
intervals (CIs) were presented by prespecified risk factor sub-
group and by combinations of risk factors. The 95% CIs were 
obtained using the Miettinen and Nurminen method [17]. The 
nonparametric Kaplan-Meier method was used to estimate 
the distribution of time to CDI recurrence for each subgroup 
within each treatment group. Observed rates were presented 
for those requiring FMT during the 12-week follow-up period, 
30-day all-cause and CDI-associated hospital readmissions, and 
mortality at 30 and 60 days after randomization.
RESULTS
Study Population
There were 1554 participants (bezlotoxumab: 781; placebo: 
773)  included in the mITT population in both studies. The 
majority of participants (75.6% [1175/1554]: 592 bezlotox-
umab, 583 placebo) had at least 1 prespecified risk factor for 
rCDI or CDI-related adverse outcomes: Approximately 36% 
had a single risk factor, approximately 27% had 2 risk factors, 
and approximately 12% had ≥3 risk factors (Table  1). In the 
group of participants with at least 1 risk factor, 497 (84.0%) and 
482 (82.7%) participants remained in the study through week 12 
in the bezlotoxumab and placebo groups, respectively. A higher 
proportion of participants with no risk factors completed the 
study (91.5% bezlotoxumab, 86.8% placebo) compared with 
participants with at least 1 risk factor. Reasons for discontinu-
ation by treatment group and by risk category are summarized 
in Supplementary Table 1. The proportion of participants who 
prematurely discontinued the study due to death was higher in 
participants with at least 1 risk factor (7.8% bezlotoxumab, 8.6% 
placebo) compared with the proportion with no risk factors 
(3.2% for both bezlotoxumab and placebo).
Demographic and clinical characteristics were similar 
between the bezlotoxumab and placebo groups when com-
paring within each of the 2 risk categories (Table 1). The par-
ticipants with at least 1 risk factor were older and a higher 
percentage had a Charlson index ≥3, had renal impairment, had 
hypoalbuminemia, and received vancomycin or fidaxomicin as 
the SOC antibiotic (Table 1) compared with the group of partic-
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Initial Clinical Cure
Treatment with bezlotoxumab did not impact the proportion of 
participants with initial clinical cure of the episode under treat-
ment with SOC antibiotics. Initial clinical cure rates were similar in 
the bezlotoxumab and placebo groups in participants with at least 
1 risk factor (79.6% vs 80.3%, respectively; difference, –0.7 [95% 
CI, –5.3 to 3.9]) and in the participants with no risk factors (81.5% 
vs 80.5%, respectively; difference, 1.0 [95% CI, –7.0 to 8.9]).
Table 1. Baseline Demographics, Clinical Characteristics, and Predefined Risk Factors, Modified Intent-to-Treat Population
Characteristic
Bezlotoxumab (N = 781) Placebo (N = 773)
No Risk Factors ≥1 Risk Factor No Risk Factors ≥1 Risk Factor
Demographics n = 189 n = 592 n = 190 n = 583
 Age, y
  Mean (SD) 46.6 (12.8) 66.7 (16.7) 48.2 (13.2) 68.5 (15.6)
  Median 51 69 52 71
  Range 20–64 18–100 19–64 18–98
  18–49 87 (46.0) 87 (14.7) 81 (42.6) 72 (12.3)
  50–64 102 (54.0) 115 (19.4) 109 (57.4) 106 (18.2)
  65–79 NA 250 (42.2) NA 253 (43.4)
  ≥80 NA 140 (23.6) NA 152 (26.1)
 Female sex 117 (61.9) 325 (54.9) 118 (62.1) 331 (56.8)
SOC antibiotic
 Metronidazole 127 (67.2) 252 (42.6) 124 (65.3) 250 (42.9)
 Vancomycin 59 (31.2) 313 (52.9) 63 (33.2) 310 (53.2)
 Fidaxomicin 3 (1.6) 27 (4.6) 3 (1.6) 23 (3.9)
Clinical characteristics
 Age ≥65 ya NA 390 (65.9) NA 405 (69.5)
 Primary CDI 146 (77.2) 278 (47.0) 145 (76.3) 255 (43.7)
 ≥1 CDI episodes in past 6 moa NA 216 (36.5) NA 219 (37.6)
 1 previous CDI episode ever 6 (3.2) 144 (24.3) 6 (3.2) 126 (21.6)
 ≥2 previous CDI episodes ever 4 (2.1) 96 (16.5) 4 (2.2) 122 (21.4)
 Severe CDI (Zar score ≥2)a,b NA 122 (20.6) NA 125 (21.4)
 Immunocompromiseda,c NA 178 (30.1) NA 153 (26.2)
 Inpatient at time of randomization 95 (50.3) 435 (73.5) 98 (51.6) 422 (72.4)
 Antibiotic used during SOC 45 (23.8) 201 (34.0) 58 (30.5) 218 (37.4)
 Antibiotic used after SOC 38 (20.1) 208 (35.1) 45 (23.7) 179 (30.7)
 Charlson index ≥3 48 (25.4) 271 (45.8) 43 (22.6) 260 (44.6)
 Renal impairmente 12 (6.3) 111 (18.8) 20 (10.5) 90 (15.4)
 Hepatic impairmentf 12 (6.3) 37 (6.3) 9 (4.7) 35 (6.0)
 Albumin <2.5 g/dL 13 (6.9) 88 (14.9) 9 (4.7) 94 (16.1)
Clostridium difficile straing
 Participants with a positive culture 112 (59.3) 378 (63.9) 114 (60.0) 372 (63.8)
 Ribotype 027, 078, or 244a NA 102 (27.0) NA 115 (30.9)
 Ribotype 027 NA 89 (23.5) NA 100 (26.9)
No. of prespecified risk factors
 0 189 (24.2) 190 (24.6)
 1 283 (36.2) 274 (35.4)
 2 220 (28.2) 208 (26.9)
 3 73 (9.3) 82 (10.6)
 4 14 (1.8) 14 (2.0)
 5 2 (0.3) 5 (0.6)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CDI, Clostridium difficile infection; NA, not analyzed; SD, standard deviation; SOC, standard of care.
aPrespecified risk factor.
bBased on the following: (1) age >60 years (1 point); (2) body temperature >38.3°C (>101°F) (1 point); (3) albumin level <2.5 g/dL (1 point); (4) peripheral white blood cell count >15 000 cells/µL 
within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care unit (2 points).
cDefined on the basis of a participant’s medical history or use of immunosuppressive therapy.
dSystemic antibiotic other than SOC antibiotic given to treat CDI.
eRenal impairment defined as serum creatinine ≥1.5 mg/dL.
fHepatic impairment defined by ≥2 of the following: (1) albumin ≤3.1 g/dL; (2) alanine aminotransferase ≥2 times the upper limit of normal (ULN); (3) total bilirubin ≥1.3 times the ULN; or (4) 
mild, moderate, or severe liver disease (as reported on the Charlson index).
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CDI Recurrence
Among participants who received placebo and achieved initial 
clinical cure, the proportion of participants who experienced 
rCDI during the 12-week follow-up period exceeded 30% for 
each of the 5 prespecified risk factors (Figure 1A). The propor-
tion of participants who experienced a recurrence in the pla-
cebo group was 20.9% among those without a risk factor and 
increased with the number of risk factors (Figure 1B), 31.3% for 
participants with 1 risk factor, and 46.1% in participants with at 
least 3 risk factors.
Bezlotoxumab reduced the rate of rCDI compared with 
placebo among participants with each of the 5 prespecified 
risk factors, and the 95% CIs excluded 0 for all compari-
sons except the ribotype 027/078/244 subgroup (Figure 1A). 
Among participants who had ≥1 risk factor, treatment with 
bezlotoxumab reduced CDI recurrences compared with 
placebo (21.2% vs 37.2%, respectively; difference, –15.9 
[95% CI, –21.6 to –10.2]; Figure  1B). The absolute reduc-
tion was –14.2%, –14.2%, and –24.8% (relative reduction: 
–45.3%, –34.5%, and –53.9%) for those with 1, 2, and ≥3 risk 
factors, respectively (95% CIs excluded 0 for all comparisons; 
Figure 1B). In contrast, among participants with no risk fac-
tors, the proportion of participants with CDI recurrences 
was similar between treatment groups (18.8% bezlotoxumab 
vs 20.9% placebo; difference, –2.1 [95% CI, –11.1 to 6.9]; 
Figure 1B).
The proportion of participants experiencing rCDI in clin-
ically relevant subpopulations is shown in Figure  2. In the 
placebo-treated participants with a single risk factor, the 
rate of rCDI ranged from 29.8% in participants experiencing 
primary CDI who had at least 1 risk factor, to 54.3% in par-
ticipants who had at least 1 prior episode of CDI and were 
immunocompromised.
In all subgroups assessed, including participants with pri-
mary CDI (with or without any prespecified risk factors), 
rCDI rates were lower in participants treated with bezlotox-
umab compared with those treated with placebo (Figure  2). 
The absolute difference in the rate of rCDI between the bez-
lotoxumab and placebo groups was highest in participants 



































Figure 1. A, Proportion of participants with Clostridium difficile infection (CDI) recurrence, by prespecified risk factor. Each subgroup includes all participants with the 
risk factor (ie, those with only 1 risk factor and those with the specified risk factor and ≥1 additional risk factor). B, Proportion of participants with CDI recurrence, by 
number of prespecified risk factors (clinical cure population). Difference and 95% confidence intervals, shown above bars, were based on the Miettinen and Nurminen 
method. Prespecified risk factors include age ≥65 years, history of CDI in the previous 6 months, immunocompromised, severe CDI, and having a strain associated with 
poor outcomes of CDI (ribotype 027, 078, or 244). †CDI history in the previous 6 months. ‡Defined on the basis of a subject’s medical history or use of immunosuppressive 
therapy. §Based on the Zar score, scored as (1) age >60 years (1 point); (2) body temperature >38.3°C (>101°F) (1 point); (3) albumin level <2.5 g/dL (1 point); (4) peripheral 
white blood cell count >15 000 cells/µL within 48 hours (1 point); (5) endoscopic evidence of pseudomembranous colitis (2 points); and (6) treatment in an intensive care 
unit (2 points). ॥Denominator is participants in the modified intent-to-treat population with a positive culture. Abbreviations: Bezlo, bezlotoxumab; CDI, Clostridium difficile 
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CI, –60.5% to –2.8%]) and was lowest in patients who were 
<65 years of age (–4.4% [95% CI, –11.2% to 2.3%]). Of note, 
the 95% CIs crossed 0 for some of these subgroups due to 
small differences (eg, younger age) or due to the limited size 
of the subgroup (eg, history of CDI and infected with ribotype 
027/078/244).
Most CDI recurrences occurred within 4 weeks of study infu-
sion (range, 63%–78% across subgroups; Figure 3). There were 
differences in the rate of rCDI at week 4 between participants 
with ≥1 risk factor who received placebo compared with par-
ticipants with ≥1 risk factor who received bezlotoxumab, and 
these differences were maintained through week 12. In partic-
ipants with no risk factors who received either placebo or bez-
lotoxumab, the time-to-event curve was similar to the curve for 
the bezlotoxumab group with ≥1 risk factor (Figure 3).
Other Outcomes
The proportion of participants who (1) had an FMT during the 
90-day follow-up period, (2) were readmitted to the hospital 
within 30 days of discharge, and (3) died within 30 or 90 days of 
study entry was higher in participants with at least 1 risk factor for 
rCDI compared with those with no risk factors (Table 2). Among 
participants in the placebo group, there were more FMTs and more 
CDI-associated 30-day hospital readmissions compared with bez-
lotoxumab participants in both risk factor categories (Table 2).
DISCUSSION
Individual characteristics such as age ≥65 years [5, 18], com-
promised immunity [7], severe CDI [8, 9], history of CDI [4], 
and infection with the BI/NAP1/027 strain [5, 10–12] have 
been shown to increase a patient’s risk for rCDI and/or CDI-
related adverse outcomes. However, previous studies have not 
investigated the impact of multiple risk factors on these out-
comes. The current analysis included data from 2 large, pro-
spective, randomized, placebo-controlled trials that enrolled 
participants with multiple risk factors [14]. Approximately 
75% of the participants enrolled in the MODIFY trials had at 
least 1 of 5 prespecified risk factors, and 40% had at least 2 
risk factors. Based on the data from the group of participants 
who received placebo, this post hoc analysis confirmed that 
Figure 2. Clostridium difficile infection (CDI) recurrence rates by risk factor subgroup (clinical cure population). Unless otherwise specified, each subgroup includes all 
patients with the risk factor(s) (ie, those with only the specified risk factor[s] and those with the specified risk factor[s] and ≥1 additional risk factor). Abbreviations: CDI 
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presence of at least 1 of the 5 prespecified risk factors increased 
the risk for rCDI, 30-day and 90-day mortality, 30-day CDI-
associated hospital readmissions, and need for FMT compared 
with having none of these 5 risk factors, with the exception 
of hypervirulent strains. Furthermore, as the number of risk 
factors increased, the proportion of placebo participants with 
rCDI also increased and was greatest in participants with at 
least 3 risk factors.
The most frequently cited risk factor for rCDI is having had 
a previous episode. The rate of rCDI in participants receiving 
placebo in the MODIFY trials who were experiencing their first 
episode was 26.5%. The rate climbed to 41.3% in participants 
Figure 3. Kaplan-Meier plot of time to Clostridium difficile infection (CDI) recurrence over 12 weeks of follow-up by high-risk-factor subgroups (modified intent-to-treat 
population). The start date of CDI recurrence was the first date of the new episode of diarrhea. For subjects who were lost to follow-up prior to a CDI recurrence, time to event 
was right-censored at the date of the last stool record. Participants who completed the 12-week follow-up period without documented CDI recurrence were censored at the 
date of the last completed stool record. For participants who failed to achieve a clinical cure for the baseline CDI episode, time to event was right-censored at the date of 
infusion of study medication (day 1). Abbreviations: Bezlo, bezlotoxumab; CDI, Clostridium difficile infection; CI, confidence interval.
Table 2. Other Outcomes
Outcome Bezlotoxumab Placebo
No Risk Factors ≥1 Risk Factor No Risk Factors ≥1 Risk Factor
FMT during follow-upa n = 189 n = 592 n = 190 n = 583
0 (0.0) 7 (1.2) 5 (2.6) 18 (3.1)
30-day readmissionsb n = 95 n = 435 n = 98 n = 422
 All-cause 20 (21.1) 103 (23.7) 20 (20.4) 120 (28.4)
 CDI-associated 2 (2.1) 25 (5.7) 4 (4.1) 54 (12.8)
Mortalityc n = 189 n = 597 n = 192 n = 589
 30-day 2 (1.1) 25 (4.2) 3 (1.6) 24 (4.1)
 90-day 6 (3.2) 48 (8.0) 6 (3.1) 53 (9.0)
Abbreviations: CDI, Clostridium difficile infection; FMT, fecal microbiota transplant.
aModified intent-to-treat (mITT) population.
bmITT population who were inpatients at the time of randomization.
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who had 1 prior episode and was 51.5% in participants with 
≥2 prior episodes. These rates are comparable with previously 
reported rates [4]. Of note, at least 50% of placebo-treated par-
ticipants who had both a recent history of CDI and at least 1 
other risk factor experienced rCDI within 12 weeks of infusion. 
While participants with primary CDI had lower rates of rCDI, 
the rate was approximately 30% in the primary CDI subgroup 
that had at least 1 risk factor, suggesting that there are some 
patients with primary CDI who may be considered to be at high 
risk for rCDI.
Older age (≥65 years) has been characterized as a risk factor 
in almost all studies reporting on risk factors for rCDI. While 
it is generally assumed that the higher rate in older patients is 
likely because they have other risk factors that contribute to 
the higher rate of rCDI compared with younger patients, in 
this analysis, almost one-third of placebo-treated participants 
with age ≥65 years as their sole risk factor experienced rCDI. 
As expected, the proportion of older placebo participants who 
experienced rCDI and had an additional risk factor was higher 
than those ≥65  years as their only risk factor (range, 33.3%–
48.3%). A lower rate of rCDI was observed in younger partici-
pants (age <65 years, 26.4%). However, the rate exceeded 30% 
in the subgroup of younger participants who had at least 1 of the 
4 other risk factors.
A major strength of this analysis was that it identified patients 
who are likely to benefit from treatment with bezlotoxumab. In 
participants with at least 1 risk factor, treatment with bezlotox-
umab reduced the proportion of participants with rCDI over 
a 12-week period compared with placebo (absolute reduction 
16%, relative reduction 43%); a larger reduction was observed 
in participants with ≥3 risk factors (absolute reduction 24.8%, 
relative reduction 54%).
The proportion of participants with no risk factors who expe-
rienced rCDI in the MODIFY trials was relatively low in both 
treatment groups (~20%). In general, participants without 1 of 
these known risk factors for rCDI at the time of diagnosis are not 
likely to benefit from bezlotoxumab. It is important to note, how-
ever, that participants with primary CDI and without one of the 
prespecified risk factors may have other risk factors such as renal 
impairment [19], inflammatory bowel disease [20], or concomi-
tant antibiotic use [21] that were not included in this analysis and 
could also benefit from bezlotoxumab therapy for prevention of 
a future recurrence. Ongoing analyses may identify other at-risk 
populations that will benefit from bezlotoxumab treatment.
Results for other post hoc endpoints are supportive of the 
benefit of bezlotoxumab in patients at high risk for rCDI or 
CDI-related adverse outcomes. Fewer bezlotoxumab-treated 
participants received an FMT during the 12-week follow-up 
period compared with the placebo-treated participants. While 
this observation is encouraging, it should be noted that FMT 
procedures were performed at only 17 trial sites, which reflects 
that the study was not limited to sites that have access to this 
procedure; additional research is needed to confirm these 
results. Bezlotoxumab also reduced the number of CDI-related 
hospital readmissions in participants with at least 1 risk factor 
compared with the placebo group (difference, –7.1%). These 
results are consistent with a previous analysis of bezlotoxumab 
data demonstrating a reduction in 30-day CDI-associated hos-
pital readmissions in those aged ≥65 years and with severe CDI 
[16]. Although the presence of risk factors increased 30- and 
90-day mortality rates, the relatively low rates observed in this 
study vs those observed in observational studies of patients with 
CDI [22, 23] may be in part due to the study entry requirement 
for participants to survive at least 72 hours, potentially biasing 
the results to the null when assessing differences in mortality.
There were limitations to this analysis. Although the clinical 
characteristics that were prespecified in the protocol are known 
risk factors for rCDI or CDI-related adverse outcomes, there 
are other risk factors for rCDI that were not included. Results 
may be different if other risk factors are considered. Although 
there were a large number of participants with at least 1 risk fac-
tor included (n = 1175), and the baseline characteristics among 
these participants across treatment groups were well balanced, 
many of the analyses presented here were conducted post hoc 
and the study was not powered for statistical significance for 
subgroup analyses. Therefore, the results should be considered 
preliminary.
In conclusion, these results demonstrate that the risk fac-
tors prespecified in the MODIFY statistical analysis plan are 
appropriate to identify patients who are at high risk for rCDI. 
While participants with at least 3 risk factors appear to have the 
greatest risk reduction with bezlotoxumab, those with only 1 
of the risk factors may also benefit from bezlotoxumab. These 
observations may help direct clinicians to patients who are most 
likely to benefit from bezlotoxumab.
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